Key statistics dashboard for Cadrenal Therapeutics, Inc. Common Stock (CVKD). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
Stock Data
| Price | $1.08 |
| Market Cap | $4M |
| Enterprise Value | $1.5M |
| Beta | 1.55 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.22 |
| Price / Book | 0.78 |
| P/S | 0.00 |
| EV/EBITDA | -0.13 |
| EV/Sales | 0.00 |
| EV/FCF | -0.14 |
| P/FCF | -0.38 |
| Earnings Yield | -366.90% |
| FCF Yield | -263.80% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -406.38% |
| Return on Assets | -206.55% |
| Return on Invested Capital | -284.81% |
| Return on Capital Employed | -284.81% |
Financial Health
| Current Ratio | 3.73 |
| Quick Ratio | 3.73 |
| Cash Ratio | 1.60 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.21 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.40 |
| Cash per share | 0.82 |
| FCF per share | -3.49 |
| Tangible Book Value per share | 1.40 |
| Dividend per share | 0.00 |
Related companies: CLGN · IBIO · ITRM · KLTO · NRSN · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of CVKD: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks